Search Result

Results for "

Cysteinyl

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Drug Metabolite (1) Endogenous Metabolite (7) Ferroptosis (4) FLAP (2) G protein-coupled Bile Acid Receptor 1 (1) Isotope-Labeled Compounds (6) Leukotriene Receptor (20) Reactive Oxygen Species (4) TNF Receptor (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (9) Inflammation/Immunology (28) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D0187

L-Glutathione reduced Maximum Cited Publications 29 Publications Verification GSH; γ-L-Glutamyl-L-Cysteinyl-glycine	Endogenous Metabolite Reactive Oxygen Species Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

HY-13315

Montelukast sodium 5+ Cited Publications MK0476	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-13315A

Montelukast 5+ Cited Publications MK0476 free base	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-W108635

*N-[S-Trityl-L-cysteinyl]glycine*	ADC Linker	Cancer
N-[S-Trityl-L-cysteinyl]glycine is a cleavable ADC linker.

HY-144345S

*L-γ-Glutamyl-L-cysteinyl-L-lysine-13C5,15N*	Isotope-Labeled Compounds	Others
L-GAMMA-glutamyl-L-cysteinyl-L-lysine- ¹³C₅, ¹⁵N is a ¹⁵N-labeled and ¹³C-labled labeled L-GAMMA-glutamyl-L-cysteinyl-L-lysine[1].

HY-123571

CP-199330	Leukotriene Receptor	Inflammation/Immunology
CP-199330 is a potent and orally active cysteinyl LT1 receptor antagonist .

HY-D0187S6

L-Glutathione reduced-15N GSH-¹⁵N; γ-L-Glutamyl-L-Cysteinyl-glycine-¹⁵N	Isotope-Labeled Compounds	Others
L-Glutathione reduced- ¹⁵N (GSH- ¹⁵N; γ-L-Glutamyl-L-cysteinyl-glycine- ¹⁵N) is ¹⁵N-labeled L-Glutathione reduced (HY-D0187). L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant that scavenges oxygen free radicals.

HY-112248

(Rac)-HAMI 3379	Leukotriene Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
(Rac)-HAMI 3379 is the racemate of HAMI 3379. HAMI 3379 is a potent and selective Cysteinyl leukotriene (CysLT₂) receptor antagonist .

HY-D0187S4

L-Glutathione reduced-13C GSH-¹³C; γ-L-Glutamyl-L-Cysteinyl-glycine-¹³C	Isotope-Labeled Compounds	Others
L-Glutathione reduced- ¹³C (GSH- ¹³C; γ-L-Glutamyl-L-cysteinyl-glycine- ¹³C) is ¹³C-labeled L-Glutathione reduced (HY-D0187). L-Glutathione reduced is an endogenous antioxidant and oxygen free radical scavenger.

HY-D0187S5

L-Glutathione reduced-d2 GSH-d₂; γ-L-Glutamyl-L-Cysteinyl-glycine-d₂	Isotope-Labeled Compounds	Others
L-Glutathione reduced-d₂ (GSH-d₂; γ-L-Glutamyl-L-cysteinyl-glycine-d₂) is deuterated-labeled L-Glutathione reduced (HY-D0187). L-Glutathione reduced is an endogenous antioxidant and oxygen free radical scavenger.

HY-13315B

Montelukast dicyclohexylamine MK0476 dicyclohexylamine	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

HY-119442

Quininib	Leukotriene Receptor	Cardiovascular Disease
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC₅₀s of 1.2 and 52 μM for CysLT₁R and CysLT₂R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents .

HY-13315AR

Montelukast (Standard)	Leukotriene Receptor	Inflammation/Immunology
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-13315BR

Montelukast (dicyclohexylamine) (Standard)	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (dicyclohexylamine) (Standard) is the analytical standard of Montelukast (dicyclohexylamine). This product is intended for research and analytical applications. Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

HY-101944

Iralukast CGP 45715A	Leukotriene Receptor	Inflammation/Immunology
Iralukast is a cysteinyl-leukotriene antagonist (CysLT) with a pK_i of 7.8 for CysLT₁.

HY-105221

Masilukast ZD-3523	Leukotriene Receptor	Inflammation/Immunology
Masilukast is an orally administered cysteinyl leukotriene D₄ (LTD₄) receptor antagonist with potential to research asthma.

HY-107609

BAY-u 9773	Leukotriene Receptor	Inflammation/Immunology
BAY-u 9773 is a non-selective antagonist of the CysLT receptors (cysteinyl leukotrienes receptors) with about the same IC₅₀ for CysLT ¹ and CysLT ². BAY-u9773 is used for the inhibition of LT responses .

HY-113446S

Leukotriene C4-d5	Endogenous Metabolite Isotope-Labeled Compounds	Cardiovascular Disease Inflammation/Immunology
Leukotriene C4-d₅ is the deuterium labeled Leukotriene C4. Leukotriene C4 is the parent cysteinyl leukotriene produced by the LTC4 synthase catalyzed conjugation of glutathione to LTA4.

HY-D0187R

L-Glutathione reduced (Standard)	Endogenous Metabolite Reactive Oxygen Species Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
L-Glutathione reduced (Standard) is the analytical standard of L-Glutathione reduced. This product is intended for research and analytical applications. L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

HY-D0187B

L-Glutathione reduced monosodium GSH monosodium; γ-L-Glutamyl-L-Cysteinyl-glycine monosodium	Endogenous Metabolite Reactive Oxygen Species Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
L-Glutathione reduced monosodium is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

HY-14460

AM679	FLAP	Inflammation/Immunology
AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC₅₀ of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratory syncytial virus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye .

HY-117854

SB 201146	Leukotriene Receptor	Inflammation/Immunology
SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .

HY-130440

Leukotriene F4	Endogenous Metabolite Leukotriene Receptor	Inflammation/Immunology
Leukotriene F4 (LTF4), is a lipid that belongs to the Cysteinyl Leukotriene (CysTL) family . Leukotriene F4 induces bronchoconstriction with an ED₅₀ of 16 μg/kg . The precursor of LTF4 is Leukotriene E4 (LTE4), which isformed from the action of a glutamyl transferase .

HY-13315S1

Montelukast-d6 sodium MK0476-d₆	Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-13315S

Montelukast-d6 MK0476-d₆ free acid	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-16780

Gemilukast ONO-6950	Leukotriene Receptor	Inflammation/Immunology
Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT₁ and CysLT₂) antagonist, with IC₅₀s of 1.7, 25 nM for human CysLT₁ and CysLT₂, respectively. Gemilukast is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-113456S

Leukotriene D4-d5	Drug Metabolite Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Leukotriene D4-d₅ is the deuterium labeled Leukotriene D4. Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4. Leukotriene D4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute hypersensitivity.

HY-112248A

HAMI 3379	Leukotriene Receptor	Cardiovascular Disease Inflammation/Immunology
HAMI 3379 is a potent and selective CysLT₂ receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation .

HY-14162

AM103 free acid	FLAP	Inflammation/Immunology
AM103 (free acid) is a selective FLAP inhibitor that can block the first step of the LT pathway, which is 5-LO activation. AM103 (free acid) can inhibit the production of LTB₄ and cysteinyl leukotrienes (CysLT). AM103 (free acid) has anti-inflammatory activity in a mouse model of chronic lung inflammation and can extend the survival time of mice injected with platelet-activating factor. AM103 (free acid) can be used for research on respiratory diseases such as asthma .

HY-165155

CysLT1 receptor antagonist-1	Leukotriene Receptor	Inflammation/Immunology
CysLT1 receptor antagonist-1 (Compound 4) is an antagonist for cysteinyl leukotriene receptor 1 (CysLT1R) with an IC₅₀ of 3.9 μM. CysLT1 receptor antagonist-1 exhibits weak agonist activity against G-protein-coupled bile acid receptor 1 (GPBAR1) with an efficact of 23% at 10 μM. CysLT1 receptor antagonist-1 can be used for asthma and allergic diseases researchs .

HY-13315R

Montelukast sodium (Standard) MK0476 (Standard)	Leukotriene Receptor	Inflammation/Immunology
Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-147086

CAY10789	Leukotriene Receptor G protein-coupled Bile Acid Receptor 1 TNF Receptor	Metabolic Disease Inflammation/Immunology
CAY10789 (compound 6) is a potent CysLT1R (cysteinyl leukotriene receptor 1) antagonist (IC₅₀=2.80 μM) and GPBAR1 (G-protein-coupled bile acid receptor 1) agonist (EC₅₀=3 μM). CAY10789 significantly reduces the adhesion of U937 cells to HAEC, reduces the expression of TNF-α. CAY10789 shows very promising metabolic stability and excellent pharmacokinetics. CAY10789 can be used for the research of colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .

HY-D0187S

L-Glutathione reduced-13C2,15N GSH-¹³C₂,¹⁵N; γ-L-Glutamyl-L-Cysteinyl-glycine-¹³C₂,¹⁵N	Endogenous Metabolite Reactive Oxygen Species Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
L-Glutathione reduced- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutathione reduced. L-Glutathione reduced (GSH) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

Cat. No.	Product Name	Type

HY-D0187

L-Glutathione reduced 25+ Cited Publications GSH; γ-L-Glutamyl-L-Cysteinyl-glycine	Cell Assay Reagents Cosmetic Peptides
L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

HY-D0187R

L-Glutathione reduced (Standard)	Cell Assay Reagents Cosmetic Peptides
L-Glutathione reduced (Standard) is the analytical standard of L-Glutathione reduced. This product is intended for research and analytical applications. L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

L-Glutathione reduced 25+ Cited Publications GSH; γ-L-Glutamyl-L-Cysteinyl-glycine	Endogenous Metabolite Reactive Oxygen Species Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

L-Glutathione reduced (Standard)	Endogenous Metabolite Reactive Oxygen Species Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
L-Glutathione reduced (Standard) is the analytical standard of L-Glutathione reduced. This product is intended for research and analytical applications. L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

Mitogenic Pentapeptide Tripalmitoyl pentapeptide	Peptides	Inflammation/Immunology
Mitogenic Pentapeptide (Tripalmitoyl pentapeptide) is an effective activator of B lymphocyte mitogen and polyclonal. Mitogen Pentapeptide is a synthetic N-terminal analog of E. coli outer membrane lipoproteins (cysteinyl-seryl-seryl-asparaginyl-alanine). Mitogenic Pentapeptide can be used for the study of immune adjuvants .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-D0187

L-Glutathione reduced 25+ Cited Publications GSH; γ-L-Glutamyl-L-Cysteinyl-glycine	Cardiovascular Disease Structural Classification Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite Reactive Oxygen Species Ferroptosis
L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

HY-D0187R

L-Glutathione reduced (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite Reactive Oxygen Species Ferroptosis
L-Glutathione reduced (Standard) is the analytical standard of L-Glutathione reduced. This product is intended for research and analytical applications. L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

HY-130440

Leukotriene F4	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite Leukotriene Receptor
Leukotriene F4 (LTF4), is a lipid that belongs to the Cysteinyl Leukotriene (CysTL) family . Leukotriene F4 induces bronchoconstriction with an ED₅₀ of 16 μg/kg . The precursor of LTF4 is Leukotriene E4 (LTE4), which isformed from the action of a glutamyl transferase .

Cat. No.	Product Name	Chemical Structure

HY-113446S

Leukotriene C4-d5
Leukotriene C4-d₅ is the deuterium labeled Leukotriene C4. Leukotriene C4 is the parent cysteinyl leukotriene produced by the LTC4 synthase catalyzed conjugation of glutathione to LTA4.

HY-113456S

Leukotriene D4-d5

Leukotriene D4-d₅ is the deuterium labeled Leukotriene D4. Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4. Leukotriene D4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute hypersensitivity.

HY-144345S

*L-γ-Glutamyl-L-cysteinyl-L-lysine-13C5,15N*
L-GAMMA-glutamyl-L-cysteinyl-L-lysine- ¹³C₅, ¹⁵N is a ¹⁵N-labeled and ¹³C-labled labeled L-GAMMA-glutamyl-L-cysteinyl-L-lysine[1].

HY-D0187S6

L-Glutathione reduced-15N
L-Glutathione reduced- ¹⁵N (GSH- ¹⁵N; γ-L-Glutamyl-L-cysteinyl-glycine- ¹⁵N) is ¹⁵N-labeled L-Glutathione reduced (HY-D0187). L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant that scavenges oxygen free radicals.

HY-D0187S4

L-Glutathione reduced-13C
L-Glutathione reduced- ¹³C (GSH- ¹³C; γ-L-Glutamyl-L-cysteinyl-glycine- ¹³C) is ¹³C-labeled L-Glutathione reduced (HY-D0187). L-Glutathione reduced is an endogenous antioxidant and oxygen free radical scavenger.

HY-D0187S5

L-Glutathione reduced-d2
L-Glutathione reduced-d₂ (GSH-d₂; γ-L-Glutamyl-L-cysteinyl-glycine-d₂) is deuterated-labeled L-Glutathione reduced (HY-D0187). L-Glutathione reduced is an endogenous antioxidant and oxygen free radical scavenger.

HY-13315S1

Montelukast-d6 sodium
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-13315S

Montelukast-d6
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-D0187S

L-Glutathione reduced-13C2,15N
L-Glutathione reduced- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutathione reduced. L-Glutathione reduced (GSH) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Cysteinyl

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products